Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 10806X102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
KKR Genetic Disorder L.P.
13D/A
Amendment 7
|
4.7% |
8/17/2026
Event 8/13/2026
|
|
| KKR Genetic Disorder L.P. | 4.2% | ||
| KKR Genetic Disorder GP LLC | 4.2% | ||
| KKR Group Partnership L.P. | 4.7% | ||
| KKR Group Holdings Corp. | 4.7% | ||
| KKR Group Co. Inc. | 4.7% | ||
| KKR & Co. Inc. | 4.7% | ||
| KKR Management LLP | 4.7% | ||
| Henry R. Kravis | 4.7% | ||
| George R. Roberts | 4.7% | ||
|
Farallon Capital Management, L.L.C.
13G/A
Amendment 1
|
5.5% |
8/3/2026
Event 6/30/2026
|
|
| Farallon Capital Management, L.L.C. | 5.5% | ||
| Farallon Capital Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||
| Four Crossings Institutional Partners V, L.P. | 0% | ||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||
| Farallon Capital (AM) Investors, L.P. | 0% | ||
| Farallon Capital F5 Master I, L.P. | 0% | ||
| Farallon Healthcare Partners Master, L.P. | 0% | ||
| Farallon Partners, L.L.C. | 0% | ||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||
| Farallon F5 (GP), L.L.C. | 0% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||
| Dapice Joshua J. | 5.5% | ||
| Dreyfuss, Philip D. | 5.5% | ||
| Dunn Hannah E. | 5.5% | ||
| Gehani, Varun N. | 5.5% | ||
| Giauque, Nicolas | 5.5% | ||
| Husen, Avner A. | 5.5% | ||
| Kim, David T. | 5.5% | ||
| Linn, Michael G. | 5.5% | ||
| Luo Patrick (Cheng) | 5.5% | ||
| Roberts, Jr., Thomas G. | 5.5% | ||
| Saito Edric C. | 5.5% | ||
| Short Daniel S. | 5.5% | ||
| Spokes, Andrew J. M. | 5.5% | ||
| Warren, John R. | 5.5% | ||
| Wehrly, Mark C. | 5.5% | ||
| BlackRock, Inc. 13G/A Amendment 5 | 4.96% |
7/27/2026
Event 6/30/2026
|
|
|
Viking Global Investors LP
13D/A
Amendment 12
|
5.0% |
7/10/2026
Event 7/9/2026
|
|
| Viking Global Investors LP | 5.0% | ||
| Viking Global Opportunities Parent GP LLC | 5.0% | ||
| Viking Global Opportunities GP LLC | 5.0% | ||
| Viking Global Opportunities Portfolio GP LLC | 5.0% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.0% | ||
| Halvorsen Ole Andreas | 5.0% | ||
| Shabet Rose Sharon | 5.0% | ||
|
Farallon Capital Partners, L.P.
13G
|
5.2% |
5/29/2026
Event 5/22/2026
|
|
| Farallon Capital Partners, L.P. | 0.4% | ||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||
| Farallon Healthcare Partners Master, L.P. | 3.0% | ||
| Farallon Partners, L.L.C. | 5.1% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||
| Farallon F5 (GP), L.L.C. | 0.1% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 3.0% | ||
| Dapice Joshua J. | 5.2% | ||
| Dreyfuss, Philip D. | 5.2% | ||
| Dunn Hannah E. | 5.2% | ||
| Gehani, Varun N. | 5.2% | ||
| Giauque, Nicolas | 5.2% | ||
| Husen, Avner A. | 5.2% | ||
| Kim, David T. | 5.2% | ||
| Linn, Michael G. | 5.2% | ||
| Luo Patrick (Cheng) | 5.2% | ||
| Roberts, Jr., Thomas G. | 5.2% | ||
| Saito Edric C. | 5.2% | ||
| Short Daniel S. | 5.2% | ||
| Spokes, Andrew J. M. | 5.2% | ||
| Warren, John R. | 5.2% | ||
| Wehrly, Mark C. | 5.2% | ||
| Janus Henderson Group PLC 13G/A Amendment 1 | 6.8% |
5/15/2026
Event 3/31/2026
|
|
| Neil Kumar 13G/A Amendment 6 | 4.6% |
4/16/2026
Event 3/31/2026
|
|
|
Viking Global Investors LP
13D/A
Amendment 11
|
6.1% |
4/2/2026
Event 3/31/2026
|
|
| Viking Global Investors LP | 6.1% | ||
| Viking Global Opportunities Parent GP LLC | 6.1% | ||
| Viking Global Opportunities GP LLC | 6.1% | ||
| Viking Global Opportunities Portfolio GP LLC | 6.1% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.1% | ||
| Halvorsen Ole Andreas | 6.1% | ||
| Shabet Rose Sharon | 6.1% | ||
| Vanguard Group Inc 13G/A Amendment 5 | 0% |
3/26/2026
Event 3/13/2026
|
|
| Janus Henderson Group PLC 13G | 5.7% |
2/17/2026
Event 12/31/2025
|
|
|
Viking Global Investors LP
13D/A
Amendment 10
|
6.8% |
2/17/2026
Event 2/12/2026
|
|
| Viking Global Investors LP | 6.8% | ||
| Viking Global Opportunities Parent GP LLC | 6.8% | ||
| Viking Global Opportunities GP LLC | 6.8% | ||
| Viking Global Opportunities Portfolio GP LLC | 6.8% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.8% | ||
| Halvorsen Ole Andreas | 6.8% | ||
| Ott David C. | 6.8% | ||
| Shabet Rose Sharon | 6.8% | ||
|
Viking Global Investors LP
13D/A
Amendment 9
|
8.2% |
11/14/2025
Event 11/14/2025
|
|
| Viking Global Investors LP | 8.2% | ||
| Viking Global Performance LLC | 0% | ||
| Viking Global Equities II LP | 0% | ||
| Viking Global Equities Master Ltd. | 0% | ||
| Viking Long Fund GP LLC | 0% | ||
| Viking Long Fund Master Ltd. | 0% | ||
| Viking Global Opportunities Parent GP LLC | 8.2% | ||
| Viking Global Opportunities GP LLC | 8.2% | ||
| Viking Global Opportunities Portfolio GP LLC | 8.2% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.2% | ||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | 0% | ||
| Halvorsen Ole Andreas | 8.2% | ||
| Ott David C. | 8.2% | ||
| Shabet Rose Sharon | 8.2% | ||
|
Viking Global Investors LP
13D/A
Amendment 8
|
9.7% |
8/14/2025
Event 8/14/2025
|
|
| Viking Global Investors LP | 9.3% | ||
| Viking Global Performance LLC | 0.1% | ||
| Viking Global Equities II LP | 0% | ||
| Viking Global Equities Master Ltd. | 0.1% | ||
| Viking Long Fund GP LLC | <0.1% | ||
| Viking Long Fund Master Ltd. | <0.1% | ||
| Viking Global Opportunities Parent GP LLC | 9.1% | ||
| Viking Global Opportunities GP LLC | 9.1% | ||
| Viking Global Opportunities Portfolio GP LLC | 9.1% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.1% | ||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | <0.1% | ||
| Halvorsen Ole Andreas | 9.7% | ||
| Ott David C. | 9.7% | ||
| Shabet Rose Sharon | 9.7% | ||
| Vanguard Group Inc 13G/A Amendment 4 | 8.7% |
7/29/2025
Event 6/30/2025
|
|
|
Viking Global Investors LP
13D/A
Amendment 7
|
9.8% |
7/1/2025
Event 6/27/2025
|
|
| Viking Global Investors LP | 9.8% | ||
| Viking Global Performance LLC | 0.2% | ||
| Viking Global Equities II LP | 0% | ||
| Viking Global Equities Master Ltd. | 0.2% | ||
| Viking Long Fund GP LLC | 0.1% | ||
| Viking Long Fund Master Ltd. | 0.1% | ||
| Viking Global Opportunities Parent GP LLC | 9.6% | ||
| Viking Global Opportunities GP LLC | 9.6% | ||
| Viking Global Opportunities Portfolio GP LLC | 9.6% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.5% | ||
| Viking Global Opportunities Liquid Portfolio Sub-Master LP | <0.1% | ||
| Halvorsen Ole Andreas | 9.8% | ||
| Ott David C. | 9.8% | ||
| Shabet Rose Sharon | 9.8% | ||
|
KKR Genetic Disorder L.P.
13D/A
Amendment 6
|
7.0% |
5/14/2025
Event 5/12/2025
|
|
| KKR Genetic Disorder L.P. | 7.0% | ||
| KKR Genetic Disorder GP LLC | 7.0% | ||
| KKR Group Partnership L.P. | 7.0% | ||
| KKR Group Holdings Corp. | 7.0% | ||
| KKR Group Co. Inc. | 7.0% | ||
| KKR & Co. Inc. | 7.0% | ||
| KKR Management LLP | 7.0% | ||
| Henry R. Kravis | 7.0% | ||
| George R. Roberts | 7.0% | ||
|
Viking Global Investors LP
13D/A
Amendment 6
|
11.7% |
3/12/2025
Event 1/31/2025
|
|
| Viking Global Investors LP | 11.7% | ||
| Viking Global Performance LLC | 0.3% | ||
| Viking Global Equities Master Ltd. | 0.3% | ||
| Viking Long Fund GP LLC | 0.1% | ||
| Viking Long Fund Master Ltd. | 0.1% | ||
| Viking Global Opportunities Parent GP LLC | 11.3% | ||
| Viking Global Opportunities GP LLC | 11.3% | ||
| Viking Global Opportunities Portfolio GP LLC | 11.3% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 11.3% | ||
| Halvorsen Ole Andreas | 11.7% | ||
| Ott David C. | 11.7% | ||
| Shabet Rose Sharon | 11.7% | ||
|
KKR Genetic Disorder L.P.
13D/A
Amendment 5
|
10.1% |
3/7/2025
Event 3/5/2025
|
|
| KKR Genetic Disorder L.P. | 10.1% | ||
| KKR Genetic Disorder GP LLC | 10.1% | ||
| KKR Group Partnership L.P. | 10.1% | ||
| KKR Group Holdings Corp. | 10.1% | ||
| KKR Group Co. Inc. | 10.1% | ||
| KKR & Co. Inc. | 10.1% | ||
| KKR Management LLP | 10.1% | ||
| Henry R. Kravis | 10.1% | ||
| George R. Roberts | 10.1% | ||
| Neil Kumar 13G/A Amendment 5 | 5.4% |
2/13/2025
Event 12/31/2024
|
|
|
Viking Global Investors LP
13D/A
Amendment 5
|
11.7% |
1/31/2025
Event 1/31/2025
|
|
| Viking Global Investors LP | 11.7% | ||
| Viking Global Performance LLC | 0.3% | ||
| Viking Global Equities Master Ltd. | 0.3% | ||
| Viking Long Fund GP LLC | 0.1% | ||
| Viking Long Fund Master Ltd. | 0.1% | ||
| Viking Global Opportunities Parent GP LLC | 11.3% | ||
| Viking Global Opportunities GP LLC | 11.3% | ||
| Viking Global Opportunities Portfolio GP LLC | 11.3% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 11.3% | ||
| Halvorsen Ole Andreas | 11.7% | ||
| Ott David C. | 11.7% | ||
| Shabet Rose Sharon | 11.7% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 12 | 11.7 k | $768 k |
| 2026 Q2 | 518 | 206 M | $14.8 B |
| 2026 Q1 | 500 | 195 M | $14.4 B |
| 2025 Q4 | 489 | 192 M | $14.5 B |
| 2025 Q3 | 432 | 185 M | $9.62 B |
| 2025 Q2 | 402 | 191 M | $8.25 B |
| 2025 Q1 | 352 | 187 M | $6.45 B |
| 2024 Q4 | 314 | 177 M | $4.85 B |
| 2024 Q3 | 291 | 174 M | $4.43 B |
| 2024 Q2 | 296 | 177 M | $4.47 B |
| 2024 Q1 | 294 | 177 M | $5.59 B |
| 2023 Q4 | 284 | 174 M | $7.02 B |
| 2023 Q3 | 256 | 162 M | $4.26 B |
| 2023 Q2 | 248 | 150 M | $2.58 B |
| 2023 Q1 | 255 | 153 M | $2.53 B |
| 2022 Q4 | 188 | 153 M | $1.17 B |
| 2022 Q3 | 196 | 145 M | $1.44 B |
| 2022 Q2 | 185 | 141 M | $1.28 B |
| 2022 Q1 | 200 | 143 M | $1.46 B |
| 2021 Q4 | 246 | 150 M | $2.50 B |
| 2021 Q3 | 229 | 140 M | $6.56 B |
| 2021 Q2 | 223 | 150 M | $9.17 B |
| 2021 Q1 | 224 | 149 M | $9.17 B |
| 2020 Q4 | 183 | 121 M | $8.61 B |
| 2020 Q3 | 140 | 118 M | $4.39 B |
| 2020 Q2 | 131 | 117 M | $3.83 B |
| 2020 Q1 | 106 | 113 M | $3.28 B |
| 2019 Q4 | 90 | 108 M | $3.68 B |
| 2019 Q3 | 78 | 103 M | $2.22 B |
| 2019 Q2 | 63 | 99.9 M | $2.70 B |